Silence Therapeutics Plc Reports A loss After Tax Of £8.2 Million In H1 FY19

Silence Therapeutics Plc (AIM: SLN) for the six months ended 30 June 2019, has reported a loss after tax of £8.2 million as compared to a loss after tax of £8.7 million in H1 2018. Net cash outflow of the company from operating activities increased to £10.3 million as compared to £8.8 million in H1 2018. Cash and cash equivalents and term deposits stood at £16.5 million, while it was £26.5 million in FY 2018.

On 12th September 2019, at the time of writing, GMT 12.28 PM, SLN shares were trading at GBX 187.00, down by 6.00 points or 3.11% against the previous day closing price.